MolDx Local Coverage Determination (LCD) And Medical Coverage Database (MCD) Parts A and B Article Updates

The comment period for the following A/B MAC LCDs will begin on May 20, 2021, and will end on July 3, 2021:

• MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes DL38966
• MolDX: Melanoma Risk Stratification Molecular Testing DL37725
•  MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer DL38985
• MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing DL38988

A link to the proposed billing and coding articles are located under the Associated Documents section of the proposed LCD.

• Billing and Coding: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes DA58652
• Billing and Coding: Melanoma Risk Stratification Molecular Testing DA56961
• Billing and Coding: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer DA58700
• Billing and Coding: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing DA58710 

Source: https://palmettogba.com/palmetto/moldxv2.nsf/DID/9QRP4SDCH9